Supplements and Featured Publications
Utilizing Antibody-Drug Conjugates and Other Novel Agents in Lung Cancer
Volume: 1
Issue: 1
Utilizing Antibody-Drug Conjugates and Other Novel Agents in Lung Cancer comprises articles and videos on experts discussing therapeutic strategies in the pipeline and on the market for their patients with non–small cell lung cancer.
On the Horizon in NSCLC: Antibody Drug Conjugates
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5